Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent activation of the RXFP1 relaxin receptor by protein and small molecule agonists.

bioRxiv : the preprint server for biology·2026
Same author

Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson's disease.

Translational neurodegeneration·2026
Same author

Coil-Tag Conjugation: A Next Gen Site-Specific ADC Fabrication Technology.

Bioconjugate insights·2026
Same author

Peptide Tag-nology for Preparation of Site-Specific Antibody-Drug Conjugates.

Bioconjugate chemistry·2026
Same author

Biosynthesis of 6-thioguanine: characterizing two intermediates involved in its thioamide formation reaction.

ACS catalysis·2026
Same author

Bioengineered systems to exploit tumor microenvironment metabolism.

Trends in cancer·2026

Related Experiment Video

Updated: Jun 5, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Bioactive stent surface coating that promotes endothelialization while preventing platelet adhesion.

Steven R Meyers1, Daniel J Kenan, Xiaojuan Khoo

  • 1Department of Biomedical Engineering, Metcalf Center for Science and Engineering, 590 Commonwealth Avenue, Boston, Massachusetts 02215, USA.

Biomacromolecules
|January 12, 2011
PubMed
Summary
This summary is machine-generated.

A novel peptide coating for stents selectively binds endothelial cells without promoting platelet adhesion. This pro-healing stent coating shows promise for improving cardiovascular device performance and patient outcomes.

More Related Videos

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Related Experiment Videos

Last Updated: Jun 5, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Area of Science:

  • Biomaterials Science
  • Cardiovascular Engineering
  • Surface Chemistry

Background:

  • Stent coatings aim to improve biocompatibility and promote healing.
  • Current coatings often lack selectivity, leading to complications like thrombosis.
  • Developing materials that mimic biological interactions is crucial for advanced medical devices.

Purpose of the Study:

  • To design and evaluate a bifunctional peptide coating for pro-healing stent applications.
  • To create a coating that selectively binds endothelial cells while preventing platelet adhesion.
  • To assess the cell-type selectivity of the peptide coating for improved stent performance.

Main Methods:

  • Synthesis of a 28-mer bifunctional peptide with polystyrene-binding and cell-binding motifs.
  • Evaluation of the peptide coating's affinity for endothelial cells and platelets in vitro.
  • Comparative analysis of the peptide coating against the RGD motif for cell adhesion.
  • Assessment of temporal selectivity between endothelial cells and smooth muscle cells.

Main Results:

  • The synthesized peptide coating demonstrated quantitative binding of endothelial cells, comparable to the RGD motif.
  • Unlike the RGD motif, the novel peptide coating did not promote platelet adherence.
  • A temporal preference for endothelial cell binding over smooth muscle cell binding was observed.
  • In vitro results indicate significant potential for the pro-healing stent coating.

Conclusions:

  • The designed bifunctional peptide coating shows potential as a pro-healing stent material.
  • The coating's selectivity for endothelial cells and non-adherence of platelets are promising for reducing stent-related complications.
  • Further in vivo studies are necessary to validate the clinical implications of the observed cell selectivity.